Results from the trial were published in the Journal of Pain Research, the Waltham, Mass.-based company said.
In the retrospective study, researchers examined data from 713 subjects using its Quell device to treat chronic pain over 60 days of use. Data was obtained from consenting device users who rated pain at a baseline before therapy and at 60 days of use. Primary outcome measures were changes in pain intensity and pain interference with sleep, activity and mood on an 11-point numerical rating scale, the company said.
Results indicated that the Quell device was used an average of 35 hours per week, and that subjects reported statistically and clinically significant improvements in pain outcomes, which exhibited a strong dose-response relationship. Approximately 60% of subjects with high device utilization reported at least a 2 point improvement in pain interference with activity or mood.
“We are pleased that the results of this large, real-world study of Quell effectiveness has been published. The findings confirm that Quell provides valuable incremental pain relief to many individuals with chronic pain. Importantly, this is the first study using data collected in the Quell Health Cloud that has been peer reviewed and published in a pain journal. We believe that our ability to leverage the Quell Health Cloud to conduct sophisticated, large scale scientific and clinical research is a substantial long term competitive advantage,” prez & CEO Dr. Shai Gozani said in a prepared statement.
In January, NeuroMetrix saw shares dip after it released 2017 earnings that missed analyst’s expectations, despite posting fourth quarter earnings that beat consensus.